Lantheus (NASDAQ:LNTH) Issues Earnings Results
Lantheus (NASDAQ:LNTH) issued its quarterly earnings results on Tuesday. The medical equipment provider reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.06, MarketWatch Earnings reports. Lantheus had a return on equity of 11.05% and a net margin of 0.12%. The company had revenue of $92.51 million during the quarter, compared to analyst estimates of $87.24 million. During the same period in the previous year, the company earned $0.36 earnings per share. The company’s quarterly revenue was up 2.0% compared to the same quarter last year.
Lantheus stock traded up $0.06 during mid-day trading on Tuesday, hitting $23.74. The stock had a trading volume of 2,232 shares, compared to its average volume of 551,996. Lantheus has a 12 month low of $10.52 and a 12 month high of $24.20. The stock has a 50-day simple moving average of $21.19 and a two-hundred day simple moving average of $16.69. The company has a current ratio of 2.25, a quick ratio of 1.79 and a debt-to-equity ratio of 0.40. The stock has a market capitalization of $1.59 billion, a PE ratio of 297.41 and a beta of 1.32.
A number of brokerages have recently commented on LNTH. SVB Leerink upped their price target on Lantheus from $26.00 to $31.00 and gave the stock an “outperform” rating in a report on Tuesday. Credit Suisse Group upped their target price on Lantheus from $14.00 to $17.00 and gave the company a “neutral” rating in a research note on Thursday, March 4th. Finally, Zacks Investment Research upgraded Lantheus from a “sell” rating to a “hold” rating in a research note on Wednesday, April 28th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $25.67.
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; and RELISTOR for opioid-induced constipation.
Read More: EV Stocks
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.